Algestone acetophenide

Algestone acetophenide, also known more commonly as dihydroxyprogesterone acetophenide (DHPA) and sold under the brand names Perlutal and Topasel among others, is a <a href="/facts/Progestin/8xMJYV3A">progestin</a> medication which is used in combination with an <a href="/facts/Estrogen_(medication)/mSKFraNu">estrogen</a> as a form of long-lasting <a href="/facts/Combined_injectable_birth_control/wtbebG3p">injectable birth control</a>. It has also been used alone, but is no longer available as a standalone medication. DHPA is not active <a href="/facts/Oral_administration/vNQcvLVx">by mouth</a> and is given once a month by <a href="/facts/Intramuscular_injection/PPNwW2wB">injection into muscle</a>.
<a href="/facts/Side_effect/PhuX2haY">Side effects</a> of DHPA are similar to those of other progestins. DHPA is a progestin, or a <a href="/facts/Synthetic_compound/gqCNaN45">synthetic</a> <a href="/facts/Progestogen_(medication)/8xMJYV3A">progestogen</a>, and hence is an <a href="/facts/Agonist/nz8U5NNp">agonist</a> of the <a href="/facts/Progesterone_receptor/B8W2o28f">progesterone receptor</a>, the <a href="/facts/Biological_target/7bakbMFR">biological target</a> of progestogens like <a href="/facts/Progesterone/WEj2TGRm">progesterone</a>. It has no other important <a href="/facts/Hormonal_agent/WFnBnINJ">hormonal</a> activity.
DHPA was discovered in 1958 and was introduced for medical use in the 1960s. It was not introduced in the <a href="/facts/United_States/P0sCdLe5">United States</a>, but it is marketed widely throughout <a href="/facts/Latin_America/Qmx9Jx2a">Latin America</a>. It was also previously available alone in <a href="/facts/Italy/tUf0PDYF">Italy</a> and as a combined injectable contraceptive in <a href="/facts/Portugal/lYzwDQ63">Portugal</a> and <a href="/facts/Spain/bIyrB8EY">Spain</a>, but has been discontinued in these countries.

Algestone acetophenide open-in-new

Algestone acetophenide